Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health, a collaboration between Ascension Texas and the University of Texas at Austin, including its Dell Medical School. This new, state-of-the-art cardiology program fully integrates all the cardiac subspecialties to create a comprehensive heart team approach in treating patients.

VIDEO: Creating an integrated heart team program in central Texas

Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health in Austin, Texas, discusses the facility's new, state-of-the-art cardiology program.

Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 

Examples of mitral annual calcification (MAC) visualized using echocardiography. Image from the journal Echocardiography.

Mitral annulus calcification more than doubles a patient’s risk of heart valve disease

"For clinicians, suspicion for valve diseases should be increased and evaluations carefully performed for patients with MAC," according to one Mayo Clinic cardiologist.

Thumbnail

Transcatheter PVL closure linked to lower 30-day mortality than surgery

Long-term mortality, meanwhile, is similar between the two treatment options.

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

Transcatheter aortic valve replacement (TAVR) patients continue to benefit from an optimized pre- and post-procedural treatment strategy that utilizes the cusp overlap technique, according to new findings presented at EuroPCR 2022 in Paris.

Cusp overlap technique, optimized treatment strategy tied to significant improvements for TAVR patients

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

Thumbnail

New guidelines detail PFO management, including when to consider closure

The new guidance document was designed to provide helpful information on a topic "surrounded by controversy." 

Displaying 481 - 488 of 914
Design by Adaptive Theme